
NYSE:EL
This summary was created by AI, based on 2 opinions in the last 12 months.
Estee Lauder (EL-N) has garnered mixed reviews from experts, with one highlighting a significant return of 68% in a short time frame, indicating successful technical and fundamental alignment at the time of investment. However, there is a cautious outlook suggesting that the stock may have peaked in its potential gains. On the other hand, another expert points to a decline in the stock's price, framing it as an opportunity for investors. They believe that with the beauty industry's growth driven by influencers, Estee Lauder, despite experiencing some setbacks, is positioned for a potential turnaround. Analysts also provide a price target of $66.95, signaling expectations of future growth. This juxtaposition of opinions indicates a mix of optimism and caution surrounding the company's performance moving forward.
It's been heavily shorted, but today's FDA approval of Pfizer gave it a boast. It's a play on cross-border travel (prominent in duty-free airports). No wonder it jumped over 1% today.
Hit fresh highs today Is up nearly 20% this year. She loves their deal with Target.